...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Biogen/Eisai Scrap Aducanumab

Study 201-"randomized Phase II clinical study in 856 patients with mild cognitive impairment (MCI) due to Alzheimer's disease or mild Alzheimer's dementia (collectively known as early Alzheimer’s disease) with confirmed amyloid pathology in the brain."

Seems to be for early-onset of the AD. How would this compare to the 250 patients in the BOM trial?

 

Koo

Share
New Message
Please login to post a reply